Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia Study of Pvs25-IMX313/Matrix-M1 Vaccine in Healthy Adults
NCT05270265Phase 1Terminated
- Sponsor
- University of Oxford
- Start
- Feb 2022
- Primary completion
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of Pvs25-IMX313 in malaria (3 arms), sponsored by University of Oxford. Primary endpoints: Number of Participants Reporting Solicited Local Reactogenicity Signs and Symptoms at 7 days, Number of Participants Reporting Solicited Systemic Reactogenicity Signs and Symptoms at 7 days and 3 more. Started Feb 2022; status: terminated.
02
Drugs
Pvs25-IMX313
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05270265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05270265.